- Global Pharma News & Resources

Worldwide Oral Proteins & Peptides Industry to 2026 - Increase in R&D by Pharmaceutical Companies Presents Opportunities -

DUBLIN--(BUSINESS WIRE)--The "Oral Proteins & Peptides Market Research Report by Drug Type, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to's offering.

The Global Oral Proteins & Peptides Market size was estimated at USD 971.92 Million in 2020 and expected to reach USD 1,096.79 Million in 2021, at a Compound Annual Growth Rate (CAGR) 13.18% to reach USD 2,043.61 Million by 2026.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Oral Proteins & Peptides Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Oral Proteins & Peptides Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Oral Proteins & Peptides Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Oral Proteins & Peptides Market?

4. What is the competitive strategic window for opportunities in the Global Oral Proteins & Peptides Market?

5. What are the technology trends and regulatory frameworks in the Global Oral Proteins & Peptides Market?

6. What is the market share of the leading vendors in the Global Oral Proteins & Peptides Market?

7. What modes and strategic moves are considered suitable for entering the Global Oral Proteins & Peptides Market?

Market Dynamics


  • Increase in prevalence of chronic diseases
  • Rise in patient preference for oral drugs
  • Growing demand for effective drugs and technology


  • High manufacturing costs and low bioavailability


  • Rise in oral peptide and protein therapeutics applications
  • Increase in R&D by pharmaceutical companies


  • Concerns related to unwanted enzymatic degradation and inherent structural complexities

Companies Mentioned

  • Allergan Plc.
  • AstraZeneca PLC
  • Biocon Limited
  • Chiasma Inc.
  • Generex Biotechnology Corp.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Proxima Concepts Limited
  • Synergy Pharmaceuticals Inc.
  • Tarsa Therapeutics Inc.

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 10-Sep-2021